PubMed COVID-19 Clinical Care

CONCLUSIONS: Pregnancy, low vaccine confidence, and government mistrust were associated with a lower likelihood of COVID-19 vaccination among reproductive-aged women in Jamaica. Future studies should evaluate the efficacy of strategies proven to

People all throughout the world have suffered from the COVID-19 pandemic. People can be infected after brief contact, so how to assess the risk of infection for everyone effectively is a tricky challenge. In view of this challenge, the combination of

The coronavirus pandemic led to the announcement of a worldwide health emergency. The SARS-CoV-2 Omicron variant, which swiftly spread worldwide, has fueled existing challenges. Appropriate medication is necessary to avoid severe SARS-CoV-2 disease

CONCLUSION: The study on innate immunity in COVID-19 is a hot topic. The USA was the most productive and influential country in this field, followed by China. The journal with the most publications was Frontiers in Immunology. "Messenger RNA,"

Objective Disease-modifying treatments (DMT) in multiple sclerosis (M.S.) may affect the course and outcome of COVID-19, but withholding them could permit disease activity. This paper aims to understand the course of COVID-19 in patients with MS

N/A.

This qualitative semi-structured interview study explores how 64 family caregivers for older adults with Alzheimer's Disease and related dementias across eight states experienced and executed caregiving decisions before and during the COVID-19

Phthalocyanine and hypericin have been previously identified as possible SARS-CoV-2 Spike glycoprotein fusion inhibitors through a virtual screening procedure. In this paper, atomistic simulations of metal-free phthalocyanines and atomistic and

Hospitalised patients with coronavirus disease 2019 (COVID-19) are at a significantly higher risk of having thromboembolic events while in hospital and in the immediate post-hospital discharge period. Based on early data from observational studies

3CL^(pro) protease from SARS-CoV-2 is a primary target for COVID-19 antiviral drug development. Here, we present a protocol for 3CL^(pro) production in Escherichia coli. We describe steps to purify 3CL^(pro), expressed as a fusion with the